WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) is pleased to announce that the Company has filed an IND (Investigational New Drug) application with the US FDA (Food and Drug Administration) to initiate a clinical trial of TectinTM, derived from tetrodotoxin (“TTX”), under a US-IND number. This will be a randomized, pharmacokinetic trial to assess the kinetics of TTX after a single subcutaneous dose in healthy volunteers, data which are required by regulatory agencies to understand the fate of the drug in the body. As the dose of TTX administered to humans is very small, no established method was sensitive enough to detect the product in biological fluids and, therefore, no kinetic data were available. Recently, an analytical method sensitive enough to assay TTX in human samples of blood and urine has been developed. This will allow the Company to proceed with this study and obtain information about TTX kinetics, data crucial to the successful development of the product.
